Probi AB (publ) (PROB.ST)
SEK 348.0
(0.0%)
SEK 348.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.55 Billion SEK | -1.24% |
| 2022 | 1.56 Billion SEK | 9.62% |
| 2021 | 1.43 Billion SEK | 15.51% |
| 2020 | 1.23 Billion SEK | -3.86% |
| 2019 | 1.28 Billion SEK | 6.63% |
| 2018 | 1.2 Billion SEK | 8.89% |
| 2017 | 1.11 Billion SEK | -8.3% |
| 2016 | 1.21 Billion SEK | 431.5% |
| 2015 | 227.88 Million SEK | 29.49% |
| 2014 | 175.98 Million SEK | 17.55% |
| 2013 | 149.71 Million SEK | 9.5% |
| 2012 | 136.72 Million SEK | 5.64% |
| 2011 | 129.43 Million SEK | -4.21% |
| 2010 | 135.11 Million SEK | 11.39% |
| 2009 | 121.3 Million SEK | 8.75% |
| 2008 | 111.54 Million SEK | 7.56% |
| 2007 | 103.7 Million SEK | 25.91% |
| 2006 | 82.36 Million SEK | -0.7% |
| 2005 | 82.94 Million SEK | -10.88% |
| 2004 | 93.07 Million SEK | 28.85% |
| 2003 | 72.23 Million SEK | -4.1% |
| 2002 | 75.31 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 1.52 Billion SEK | -3.68% |
| 2024 Q2 | 1.58 Billion SEK | 2.92% |
| 2024 Q1 | 1.53 Billion SEK | -0.86% |
| 2023 Q3 | 1.58 Billion SEK | -0.38% |
| 2023 FY | 1.55 Billion SEK | -1.24% |
| 2023 Q2 | 1.59 Billion SEK | 0.35% |
| 2023 Q1 | 1.59 Billion SEK | 1.29% |
| 2023 Q4 | 1.55 Billion SEK | -2.47% |
| 2022 Q3 | 1.64 Billion SEK | 6.32% |
| 2022 Q2 | 1.54 Billion SEK | 6.67% |
| 2022 FY | 1.56 Billion SEK | 9.62% |
| 2022 Q4 | 1.56 Billion SEK | -4.48% |
| 2022 Q1 | 1.44 Billion SEK | 1.19% |
| 2021 Q3 | 1.36 Billion SEK | 3.97% |
| 2021 Q2 | 1.3 Billion SEK | -1.59% |
| 2021 Q1 | 1.32 Billion SEK | 7.26% |
| 2021 Q4 | 1.43 Billion SEK | 5.25% |
| 2021 FY | 1.43 Billion SEK | 15.51% |
| 2020 Q3 | 1.28 Billion SEK | -2.03% |
| 2020 Q1 | 1.37 Billion SEK | 6.33% |
| 2020 FY | 1.23 Billion SEK | -3.86% |
| 2020 Q2 | 1.31 Billion SEK | -4.41% |
| 2020 Q4 | 1.23 Billion SEK | -3.45% |
| 2019 Q4 | 1.28 Billion SEK | -1.84% |
| 2019 FY | 1.28 Billion SEK | 6.63% |
| 2019 Q3 | 1.31 Billion SEK | 4.74% |
| 2019 Q2 | 1.25 Billion SEK | -0.94% |
| 2019 Q1 | 1.26 Billion SEK | 4.7% |
| 2018 FY | 1.2 Billion SEK | 8.89% |
| 2018 Q4 | 1.2 Billion SEK | 1.43% |
| 2018 Q3 | 1.19 Billion SEK | -3.07% |
| 2018 Q2 | 1.23 Billion SEK | 8.29% |
| 2018 Q1 | 1.13 Billion SEK | 2.27% |
| 2017 Q4 | 1.11 Billion SEK | -0.1% |
| 2017 Q1 | 1.23 Billion SEK | 2.33% |
| 2017 Q3 | 1.11 Billion SEK | -3.53% |
| 2017 Q2 | 1.15 Billion SEK | -7.01% |
| 2017 FY | 1.11 Billion SEK | -8.3% |
| 2016 FY | 1.21 Billion SEK | 431.5% |
| 2016 Q1 | 255.06 Million SEK | 11.93% |
| 2016 Q3 | 1.11 Billion SEK | 329.68% |
| 2016 Q2 | 258.78 Million SEK | 1.46% |
| 2016 Q4 | 1.21 Billion SEK | 8.93% |
| 2015 Q1 | 213.56 Million SEK | 21.35% |
| 2015 FY | 227.88 Million SEK | 29.49% |
| 2015 Q4 | 227.88 Million SEK | 3.56% |
| 2015 Q3 | 220.06 Million SEK | 4.36% |
| 2015 Q2 | 210.86 Million SEK | -1.27% |
| 2014 FY | 175.98 Million SEK | 17.55% |
| 2014 Q4 | 175.98 Million SEK | 5.25% |
| 2014 Q2 | 154.46 Million SEK | 1.01% |
| 2014 Q1 | 152.91 Million SEK | 2.14% |
| 2014 Q3 | 167.2 Million SEK | 8.25% |
| 2013 Q3 | 145.11 Million SEK | 3.27% |
| 2013 FY | 149.71 Million SEK | 9.5% |
| 2013 Q4 | 149.71 Million SEK | 3.17% |
| 2013 Q2 | 140.51 Million SEK | -1.21% |
| 2013 Q1 | 142.23 Million SEK | 4.03% |
| 2012 Q1 | 137.34 Million SEK | 6.12% |
| 2012 Q4 | 136.72 Million SEK | 3.02% |
| 2012 Q3 | 132.71 Million SEK | 1.59% |
| 2012 Q2 | 130.64 Million SEK | -4.88% |
| 2012 FY | 136.72 Million SEK | 5.64% |
| 2011 Q3 | 127.07 Million SEK | -0.22% |
| 2011 Q2 | 127.35 Million SEK | -3.19% |
| 2011 Q4 | 129.43 Million SEK | 1.85% |
| 2011 FY | 129.43 Million SEK | -4.21% |
| 2011 Q1 | 131.55 Million SEK | -2.63% |
| 2010 Q4 | 135.11 Million SEK | 0.0% |
| 2010 FY | 135.11 Million SEK | 11.39% |
| 2009 FY | 121.3 Million SEK | 8.75% |
| 2008 FY | 111.54 Million SEK | 7.56% |
| 2007 FY | 103.7 Million SEK | 25.91% |
| 2006 FY | 82.36 Million SEK | -0.7% |
| 2005 FY | 82.94 Million SEK | -10.88% |
| 2004 FY | 93.07 Million SEK | 28.85% |
| 2003 FY | 72.23 Million SEK | -4.1% |
| 2002 FY | 75.31 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AcuCort AB | 58.5 Million SEK | -2549.936% |
| AlzeCure Pharma AB (publ) | 32 Million SEK | -4744.843% |
| BioGaia AB (publ) | 2.33 Billion SEK | 33.55% |
| Enzymatica AB (publ) | 125.91 Million SEK | -1131.344% |
| Enorama Pharma AB (publ) | 34.38 Million SEK | -4408.937% |
| Gabather AB (publ) | 2.93 Million SEK | -52688.492% |
| Klaria Pharma Holding AB (publ.) | 73.12 Million SEK | -2020.347% |
| Moberg Pharma AB (publ) | 634.73 Million SEK | -144.26% |
| Nanexa AB (publ) | 132.25 Million SEK | -1072.262% |
| Newbury Pharmaceuticals AB (publ) | 90.87 Million SEK | -1606.153% |
| ODI Pharma AB | 12.27 Million SEK | -12530.54% |
| Orexo AB (publ) | 786.6 Million SEK | -97.101% |
| Swedencare AB (publ) | 9.52 Billion SEK | 83.718% |
| Swedish Orphan Biovitrum AB (publ) | 74.02 Billion SEK | 97.906% |
| Toleranzia AB | 160.42 Million SEK | -866.42% |
| Vivesto AB | 355.87 Million SEK | -335.657% |